Moderna-Merck cancer vaccine makes progress

By Associated Press

Dec 15, 2022 12:05 am

MODERNA'S stock soared on Tuesday after the coronavirus vaccine maker reported progress in developing a preventive shot for a deadly form of skin cancer.

The company said a possible melanoma vaccine that it was studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically removed.

A Moderna sign is seen above the entrance to the company’s building in Cambridge, Massachusetts on May 18, 2020. AP FILE PHOTO

Already have an active account? Log in here to continue reading.
Or
Subscribe to the Premium Subscription plan to access this subscriber-exclusive article.

Related Articles

PBCom raises P7.7B from peso bond offer

China files complaint at WTO over EV tariffs

Boeing strike ends as workers accept contract

Taiwanese happy to keep capital at home

Indonesia's Q3 GDP rises 4.95%

Sun Life Q3 profit beats expectation

Toyota to post first profit drop in 2 years